| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 7511156 | International Journal of Drug Policy | 2018 | 9 Pages |
Abstract
HCV care in the interferon-era affords identity transformations for those receiving and providing treatment. Biomedical promise linked to the increasing pharmaceuticalisation of HCV treatment has disruptive potential, shifting how care is practised and potentially the realisation of non-clinical treatment outcomes.
Related Topics
Health Sciences
Medicine and Dentistry
Psychiatry and Mental Health
Authors
Magdalena Harris, Tim Rhodes,